drugset / Trial / NCT07438067
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
NaSingle-groupOpen-labelTreatment
Summary
This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplantation (Allo-HSCT). The study aims to determine the maximum tolerated dose (MTD) or optimal biological dose (OBD) of EBV-AST cells and assess their safety, tolerability, and preliminary efficacy in treating EBV-DNA viremia. The study will involve a 3+3 dose escalation design to evaluate three different dosages of EBV-AST cell infusion. The study is expected to provide important insights into the clinical application of cell-based therapies for EBV infections.
Timeline
- Start
- 2025-03-26
- Primary completion
- 2028-03-26
- Completion
- 2028-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBV-AST cell | Cell therapy | 300000 cells/kg | — |
| Subject | EBV-AST cell | Cell therapy | 1e+06 cells/kg | — |
| Subject | EBV-AST cell | Cell therapy | 3e+06 cells/kg | — |